nfcol.net Neurofibromatosis Clinical Reference · EN / ES
NF1 Criteria NF2 & SWN MEK Therapy Checkup Schedule Archive
EN · Español
Clinical Handbook › Global NF Clinics & Drug Access

Global Multidisciplinary NF Centers and International Drug Access

How to locate accredited neurofibromatosis clinics across the Americas, Europe, and Asia, alongside comparative public-formulary access for oral MEK1/2 inhibitors.

International Referral Networks · CTF NFCN / ERN GENTURIS / Orphan Formularies
Multidisciplinary clinical specialists walking through the sunlit atrium of an academic medical center

1. Why Coordinated NF Clinics Outperform Fragmented Care

Care Delivery Evidence: Accredited multidisciplinary neurofibromatosis clinics coordinate neuro-oncology, medical genetics, neuro-ophthalmology, skull-base neurosurgery, orthopedics, and volumetric neuroradiology in a single review loop, preventing both missed MPNST escalations and unnecessary surgeries on benign lesions.

Published survival analyses in NF2-related schwannomatosis demonstrate significantly lower perioperative morbidity and longer functional hearing preservation among patients managed at high-volume specialty centers compared with community centers seeing fewer than five cases per year.

2. Accredited Regional NF Clinic Networks Worldwide

Region Official Accredited Network / Reference Hubs Core Capabilities
United States & Canada Children's Tumor Foundation NF Clinic Network (NFCN) (>70 centers including Johns Hopkins, MGH, NIH NCI Pediatric Oncology Branch, UAB, UCSF, SickKids Toronto) 3D volumetric MRI, pediatric & adult MEK trials, NF2 skull-base & ABI/CI teams, MPNST sarcoma boards.
European Union & UK ERN GENTURIS (European Reference Network across Leuven, Paris Hôpital Henri-Mondor, Hamburg-Eppendorf, Madrid, Barcelona) & NHS Highly Specialised NF1/NF2 Services (Manchester, Guy's & St Thomas', Cambridge, Oxford) Nationally funded bevacizumab & selumetinib pathways, centralized RNA-based NF1/SPRED1 diagnostics.
Latin America (Colombia, Mexico, Argentina, Brazil) Academic genetics & pediatric oncology institutes in Bogotá (Instituto de Genética Humana / Hospital Universitario San Ignacio), Ciudad de México (INP / INCMNSZ), Buenos Aires (Hospital Garrahan / Hospital Italiano), São Paulo (HC-FMUSP) Orphan-disease statutory registries (e.g., Colombia Ley 1392 Enfermedades Huérfanas), Spanish genetic counseling & named-patient MEK pathways.
East Asia (China, Japan, South Korea) Tertiary NF multidisciplinary programs in Shanghai (Ninth People's Hospital / Xinhua Hospital), Beijing (Tiantan / PUMCH), Tokyo, and Seoul High-volume craniofacial plexiform reconstruction, nerve-sparing skull-base microsurgery, and national reimbursement formularies.

3. Global MEK1/2 Inhibitor Pricing and Reimbursement Landscape

Access to continuous multi-year oral MEK therapy varies substantially across health systems:

  • United States: Wholesale acquisition cost (WAC) for commercial selumetinib (Koselugo) and mirdametinib (Gomekli) ranges roughly from $18,000 to $24,000 USD per 28-day cycle prior to insurer negotiation, covered through Medicaid, commercial specialty tiers (requiring volumetric MRI + inoperable PN prior-authorization documentation), and manufacturer copay/bridge assistance.
  • Europe, UK, & National Universal Formularies: Reimbursed under EMA/MHRA orphan designations and national HTA agreements at negotiated public health prices; similarly, inclusion of selumetinib on China's National Reimbursement Drug List (NRDL) sharply reduced domestic out-of-pocket costs compared with unsubsidized retail pricing.
  • Latin America: In Colombia, NF1 and NF2-SWN are officially codified on the Ministry of Health national rare/orphan diseases list, enabling statutory coverage applications (MIPRES) when prescribed by a multidisciplinary genetics or oncology board.

Frequently Asked Clinical Questions

What documentation do insurers typically require to approve Koselugo or Gomekli?

Prior authorization generally requires confirmed NF1 diagnosis (2021 clinical criteria or genetic report), MRI documentation of an incompletely resectable plexiform neurofibroma, documented clinical morbidity (pain, motor deficit, airway/vision risk, or disfigurement), and baseline echocardiogram LVEF plus ophthalmic OCT clearance.

Are NF1 and NF2 recognized under statutory rare-disease protections in Latin America?

Yes. Several Latin American health systems—including Colombia under Ley 1392 for Orphan Diseases—formally list Neurofibromatosis Type 1 and NF2-related schwannomatosis as protected rare conditions eligible for specialist referral and orphan medication pathways.

Key Consensus Guidelines & Primary Sources

  1. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506–1513. PubMed 34012067.
  2. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genetics in Medicine. 2022;24(9):1967–1977. PubMed 35674741.
  3. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas (SPRINT Phase II). New England Journal of Medicine. 2020;382(15):1430–1442. PubMed 32187457.
  4. Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025;43(7):758–769. PubMed 39514828.
  5. Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1 (American Academy of Pediatrics). Pediatrics. 2019;143(5):e20190660. PubMed 30988031.